|
Wilkins A, Mossop H, Syndikus I, Khoo V, Bloomfield D, Parker C, et al. |
Hypofractionated radiotherapy versus conventionally fractionated radiothera... |
Tuesday, November 3, 2015 |
The Lancet Oncology |
|
Rintoul RC, Treasure T, Macbeth F |
Multimodal treatment for malignant pleural mesothelioma |
Friday, November 6, 2015 |
The Lancet Oncology |
|
Ajithkumar T, Parkinson C, Fife K, Corrie P, Jefferies S |
Evolving treatment options for melanoma brain metastases |
Monday, October 5, 2015 |
The Lancet Oncology |
|
Emma L O'Dowd, Richard W Lee , Ahsan R Akram, Emily C Bartlett, Stephe... |
Defining the road map to a UK national lung cancer screening programme |
|
The Lancet Oncology |
|
Wong HH, Halford S |
Dose-limiting toxicity and maximum tolerated dose: still fit for purpose? |
Monday, October 5, 2015 |
The Lancet Oncology |
|
Lamb AD, Bratt O |
Towards ""next-generation"" prostate cancer screening |
Saturday, November 14, 2015 |
The Lancet Oncology |
|
Basset-Seguin N, Hauschild A, Grob JJ, Kunstfeld R, Dreno B, Mortier L, et ... |
Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-p... |
Wednesday, May 20, 2015 |
The Lancet Oncology |
|
Motzer RJ, Hutson TE, Glen H, Michaelson MD, Molina A, Eisen T, et al. |
Lenvatinib, everolimus, and the combination in patients with metastatic ren... |
Wednesday, October 21, 2015 |
The Lancet Oncology |
|
Easton DF, Pharoah PD, Antoniou AC, Tischkowitz M, Tavtigian SV, Nathanson ... |
Gene-panel sequencing and the prediction of breast-cancer risk |
Thursday, May 28, 2015 |
The New England journal of medicine |
|
Ortmann CA, Kent DG, Nangalia J, Silber Y, Wedge DC, Grinfeld J, et al. |
Effect of mutation order on myeloproliferative neoplasms |
Thursday, February 12, 2015 |
The New England journal of medicine |
